AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 165 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is 0.31 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $36,342,000 | -1.5% | 870,876 | +24.7% | 0.01% | -16.7% |
| Q3 2016 | $36,880,000 | +37.2% | 698,214 | +8.8% | 0.01% | +50.0% |
| Q2 2016 | $26,887,000 | +8.2% | 641,781 | +4.9% | 0.00% | 0.0% |
| Q1 2016 | $24,848,000 | -37.6% | 612,020 | -0.3% | 0.00% | -42.9% |
| Q4 2015 | $39,838,000 | -7.7% | 613,649 | +0.3% | 0.01% | -12.5% |
| Q3 2015 | $43,177,000 | -5.1% | 611,653 | +49.5% | 0.01% | +14.3% |
| Q2 2015 | $45,478,000 | +47.5% | 409,196 | +25.2% | 0.01% | +40.0% |
| Q1 2015 | $30,824,000 | -4.2% | 326,872 | +13.8% | 0.01% | 0.0% |
| Q4 2014 | $32,169,000 | +273.3% | 287,122 | +104.4% | 0.01% | +400.0% |
| Q3 2014 | $8,617,000 | +24.0% | 140,456 | -7.4% | 0.00% | 0.0% |
| Q2 2014 | $6,951,000 | +132.9% | 151,705 | +99.0% | 0.00% | 0.0% |
| Q1 2014 | $2,985,000 | +53.5% | 76,247 | -6.1% | 0.00% | – |
| Q4 2013 | $1,944,000 | -17.0% | 81,168 | -3.1% | 0.00% | – |
| Q3 2013 | $2,341,000 | – | 83,722 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
| Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
| Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
| BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
| Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
| Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
| Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
| BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
| Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
| HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |